USANA Health Sciences, Inc. (NYSE:USNA) Director Myron W. Wentz sold 17,107 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $65.42, for a total value of $1,119,139.94. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
USANA Health Sciences, Inc. (NYSE:USNA) opened at $65.85 on Tuesday. USANA Health Sciences, Inc. has a fifty-two week low of $52.55 and a fifty-two week high of $71.00. The company has a market capitalization of $1,569.11, a price-to-earnings ratio of 17.30 and a beta of 1.07.
USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.91 by $0.11. The business had revenue of $261.77 million for the quarter, compared to analyst estimates of $259.52 million. USANA Health Sciences had a return on equity of 26.38% and a net margin of 8.79%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.40 EPS. analysts expect that USANA Health Sciences, Inc. will post 3.7 earnings per share for the current year.
USANA Health Sciences announced that its Board of Directors has initiated a share repurchase program on Tuesday, July 25th that allows the company to buyback $64.60 million in shares. This buyback authorization allows the company to purchase up to 46% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.
A number of research analysts have weighed in on USNA shares. Pivotal Research raised their price objective on USANA Health Sciences from $70.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, October 25th. BidaskClub upgraded USANA Health Sciences from a “sell” rating to a “hold” rating in a report on Thursday, October 26th.
Large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA increased its position in shares of USANA Health Sciences by 13.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,111 shares of the company’s stock worth $135,000 after purchasing an additional 245 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of USANA Health Sciences by 124.7% during the 1st quarter. Victory Capital Management Inc. now owns 2,117 shares of the company’s stock worth $122,000 after purchasing an additional 1,175 shares during the last quarter. Creative Planning increased its position in shares of USANA Health Sciences by 528.0% during the 2nd quarter. Creative Planning now owns 2,512 shares of the company’s stock worth $161,000 after purchasing an additional 2,112 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of USANA Health Sciences during the 2nd quarter worth about $162,000. Finally, Eqis Capital Management Inc. acquired a new stake in shares of USANA Health Sciences during the 2nd quarter worth about $210,000. 44.54% of the stock is owned by hedge funds and other institutional investors.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.